Evidence map›Paper›PMID 38129991›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2024

Screening of Environmental Chemicals to Characterize Exposures in Participants With Systemic Lupus Erythematosus.

Cristina M Lanata, Kimberly E Taylor, James Hurst-Hopf, Joanne Nititham, Ashira Blazer, Laura Trupin, Patricia Katz, Maria Dall'Era, Jinoos Yazdany, Sharon A Chung and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Cristina M LanataNational Human Genome Research Institute, NIH, Bethesda, Maryland.ORCID 0000-0002-6017-4921
Kimberly E TaylorUniversity of California, San Francisco.
James Hurst-HopfSeer Inc., Redwood City, California.
Joanne NitithamNational Human Genome Research Institute, NIH, Bethesda, Maryland.
Ashira BlazerHospital for Special Surgery, New York City.
Laura TrupinUniversity of California, San Francisco.
Patricia KatzUniversity of California, San Francisco.ORCID 0000-0002-8146-2519
Maria Dall'EraUniversity of California, San Francisco.
Jinoos YazdanyUniversity of California, San Francisco.ORCID 0000-0002-3508-4094
Sharon A ChungUniversity of California, San Francisco.ORCID 0000-0002-2238-2287
Dimitri AbrahamssonNew York University Grossman School of Medicine, New York City.
Roy GeronaUniversity of California, San Francisco.
Lindsey A CriswellNational Human Genome Research Institute, NIH, Bethesda, Maryland.
University of California, San Francisco · USNational Institutes of Health · USCodexis (United States) · USHospital for Special Surgery · USNew York University · US

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Genomic studies of Systemic Lupus ErythematosusZIAHG200416 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI CRISWELL, LINDSEY · 2021 to 2025
$7.0M
Racial/ethnic and socioeconomic disparities in biologic and clinical SLE outcomesU01DP005120 · DP · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALL'ERA, MARIA, YAZDANY, JINOOS · 2014 to 2018
$4.8M
Racial/ethnic and socioeconomic disparities in biologic and clinical SLE outcomesU01DP006701 · DP · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALL'ERA, MARIA, YAZDANY, JINOOS · 2022 to 2025
$3.6M
Advancing Quality and Outcomes Measurement in RheumatologyK24AR074534 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany · 2019 to 2026
$1.5M
SLE-AWARE: SLE-- A Window into APOL1 Regulation andExpressionK23AI163359 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLAZER, ASHIRA DESHON · 2021 to 2025
$990k
Non-target analysis of maternal and cord blood samples: Advancing computational tools and discovering novel chemicalsR00ES032892 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ABRAHAMSSON, DIMITRI · 2023 to 2025
$745k
Non-target analysis of maternal and cord blood samples: Advancing computational tools and discovering novel chemicalsK99ES032892 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ABRAHAMSSON, DIMITRI · 2021 to 2022
$200k
CDC HHS U01DP005120Intramural Research Program of the National Human Genome Research Institute, NIHLupus Research AllianceNCCDPHP CDC HHS U01 DP005120NCCDPHP CDC HHS U01 DP006701NIAID NIH HHS K23 AI163359NIAMS NIH HHS K24 AR074534NIAMS NIH HHS P30 AR070155NIAMS NIH HHS P30-AR-070155NIEHS NIH HHS K99 ES032892NIEHS NIH HHS R00 ES032892Rheumatology Research Foundation Scientist Development Award
6 · The paper itself

Abstract

objectiveThere is a need to characterize exposures associated with the pathogenesis of systemic lupus erythematosus (SLE). In this pilot study, we explore a hypothesis-free approach that can measure thousands of exogenous chemicals in blood ("exposome") in patients with SLE and unaffected controls.

methodsThis cross-sectional study analyzed a cohort of patients with prevalent SLE (n = 285) and controls (n = 106). Plasma was analyzed by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). Mass spectrometry features present in at least 25% of all samples were selected for association analysis (n = 2,737). Features were matched to potential chemicals using available databases. Association analysis of abundances of features with SLE status was performed, adjusting for age and sex. We also explored features associated with SLE phenotypes, sociodemographic factors, and current medication use.

resultsWe found 30 features significantly associated with SLE status (Bonferroni P < 0.05). Of these, seven matched chemical names based on databases. These seven features included phthalate metabolites, a formetanate metabolite, and eugenol. The abundance of acid pesticides differed between patients with SLE and controls (Bonferroni P < 0.05). Two unmatched features were associated with a history of lupus nephritis, and one with anti-double-stranded DNA antibody production (Bonferroni P < 0.05). Seventeen features varied by self-reported race and ethnicity, including a polyfluoroalkyl substance (analysis of variance P < 1.69 × 10

conclusionThis proof-of-concept study demonstrates that LC-QTOF/MS is a powerful tool that agnostically detects circulating exogenous compounds. These analyses can generate hypotheses of disease-related exposures for future prospective, longitudinal studies.

Indexed as

Environmental ExposureLupus Erythematosus, SystemicAdultCase-Control StudiesChromatography, LiquidCross-Sectional StudiesExposomeFemaleHumansMaleMass SpectrometryMiddle AgedPhthalic AcidsPilot Projectsphthalic acidPhthalic Acids

Identifiers

PMID38129991
PMCPMC11136608
OpenAlexW4390110403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.